@DiamondGoddessYYC this little abstract is for you. It was presented at the European Society of Gynecologic cancer 2025- just now. I always scan for new things. Looks like radiation is a good option. So, lay nicely and still and let them blast your lesions away. You can mindset your itchiness. Maybe you can listen to some music??
Targeted Local Therapies for Oligometastatic Disease
Macchia and colleagues35 presented the MITO-RT3/RAD phase II
trial, assessing stereotactic radiotherapy for parenchymal lesions in
oligometastatic ovarian cancer. The study included 88 patients with
127 lesions between 2020 and 2024. The overall 12- and 24-
month local control were 81.6% and 68.8%, respectively. The
objective response rate was 85% (55.9% complete and 29.1%
partial), with an overall clinical benefit rate of 96%. Achieving a
complete response had strong prognostic value, with 12-month
local control reaching 96% in complete responders versus 61.4%
in others. These results emphasize the importance of maximizing
efforts to achieve complete response. The 12- and 24-month
progression-free survival rates were 34.9% and 14.6%, respectively,
whereas the overall survival rates were 91.5% and 76.4%,
respectively. Treatment-free interval rates were 44.1% and 38.5%
at 12 and 24 months, respectively. Acute radiation-related toxicity
occurred in 20.5% (grade 2), and late toxicities in 4.5% (grade
2), with no grade 3 events. These findings support the feasibility
of ablative stereotactic radiotherapy with minimal toxicity.